Paris, France, September 28, 2023 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies for CNS (Central Nervous System) and eye diseases, announces that CEO Rodolphe Clerval will be presenting to investors and peers at the following Investor and Industry conferences:
In addition, scientific and clinical data from Coave’s plateform and pipeline programs will be presented at the following Scientific and Medical Conferences:
About Coave Therapeutics
At Coave Therapeutics, we are leading the transition of genetic medicine from rare to prevalent conditions, starting with neurodegenerative and eye diseases. The Company’s proprietary Advanced Vectors-Ligand Conjugates (‘ALIGATER’) platform introduces chemical modifications onto AAV capsids or Lipid Nanoparticles (LNPs), overcoming the limitations of current vectors on efficacy, safety, and manufacturability.
With low doses and optimized routes of administration, our conjugated vectors have demonstrated markedly improved transduction and biodistribution in the central nervous system and the eye across different species. Our diverse pipeline of novel genetic medicines can potentially transform the lives of people afflicted by rare and prevalent neurodegenerative and ocular diseases – including genetically and non-genetically defined indications.
Headquartered in Paris, France, Coave Therapeutics is backed by leading international life sciences investors. For more information about the science, pipeline, and people, please visit www.coavetx.com and follow us on LinkedIn.
Rodolphe Clerval, CEO
Sylvie Berrebi, Leila Adlam, Mark Swallow
Tel: +44 203 928 6900